Stevanato Group S.p.A. STVN PHARMA
Company Overview
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Why Investors Should Care
Operating margin of 17.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.29.
Recent Developments
- Dec 2025 Revenue of $1.19B (+7.4% YoY); net profit $139.84M.
- Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings -26.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.4%, profit CAGR -0.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.44% |
| 1 Year: | 7.80% |
Compounded Profit Growth
| 5 Years: | -0.71% |
| 1 Year: | -26.50% |
Stock Price Performance
| 1 Year: | -8.80% |
| 6 Months: | +30.89% |
| 3 Months: | +13.30% |
| 1 Month: | +0.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)43.30 · Neutral
P/E of 36.29 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -0.7% CAGR over 5 years.
- Trading 26.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STVN Stevanato Group S.p.A. PHARMA | 20.32 | 36.29 | $1.01B | 0.27% | 9.90% | 9.13% | 6.44% | -0.71% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 256.60M | 280.00M | 303.17M | 346.48M | 273.57M |
| Cost of Revenue | 186.71M | 201.40M | 214.67M | 239.58M | 198.40M |
| Gross Profit | 69.89M | 78.60M | 88.50M | 106.90M | 75.18M |
| Operating Expenses | 35.26M | 37.20M | 35.78M | 36.81M | 36.44M |
| Operating Income | 34.63M | 41.40M | 52.72M | 70.08M | 38.74M |
| EBITDA | 57.16M | 50.60M | 50.90M | 91.95M | 65.06M |
| Interest Expense | 1.43M | 11.50M | 1.77M | 1.59M | 1.17M |
| Pretax Income | 35.11M | 39.10M | 49.13M | 65.76M | 39.24M |
| Tax Provision | 8.60M | 9.40M | 13.06M | 18.21M | 11.21M |
| Net Income | 26.52M | 29.70M | 36.06M | 47.55M | 28.03M |
| Diluted EPS | 0.10 | 0.11 | 0.13 | 0.17 | 0.10 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 983.68M | 1.09B | 1.10B | 1.19B |
| Cost of Revenue | - | 663.88M | 745.46M | 801.72M | 842.41M |
| Gross Profit | - | 319.80M | 339.89M | 302.32M | 343.88M |
| Operating Expenses | - | 127.37M | 139.17M | 141.18M | 145.07M |
| Operating Income | - | 192.43M | 200.72M | 161.14M | 198.80M |
| EBITDA | - | 256.40M | 272.35M | 247.80M | 284.15M |
| Interest Expense | - | 3.94M | 4.32M | 6.86M | 6.48M |
| Pretax Income | - | 187.64M | 189.55M | 160.29M | 189.11M |
| Tax Provision | - | 44.62M | 43.86M | 42.52M | 49.27M |
| Net Income | - | 142.85M | 145.63M | 117.78M | 139.84M |
| Diluted EPS | - | 0.54 | 0.55 | 0.43 | 0.51 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.66B | 2.07B | 2.33B | 2.54B |
| Current Assets | - | 845.77M | 861.89M | 880.12M | 943.35M |
| Cash & Equivalents | - | 228.74M | 69.60M | 98.27M | 130.60M |
| Inventory | - | 213.25M | 255.32M | 245.22M | 268.25M |
| Receivables | - | 212.73M | 301.77M | 295.95M | 302.69M |
| Total Liabilities | - | 663.79M | 938.93M | 924.43M | 1.06B |
| Current Liabilities | - | 462.50M | 574.39M | 477.47M | 535.88M |
| Long Term Debt | - | 133.75M | 242.05M | 305.23M | 337.78M |
| Total Debt | - | 218.37M | 396.59M | 428.97M | 468.90M |
| Total Equity | - | 996.13M | 1.13B | 1.40B | 1.49B |
| Shares Outstanding | - | 295.54M | 265.47M | 302.84M | 302.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 103.31M | 105.21M | 155.78M | 286.08M |
| Investing Cash Flow | - | -242.95M | -421.22M | -310.21M | -272.92M |
| Financing Cash Flow | - | -44.54M | 158.03M | 183.22M | 22.06M |
| Capital Expenditure | - | -243.13M | -441.93M | -313.57M | -275.03M |
| Free Cash Flow | - | -139.81M | -336.72M | -157.79M | 11.04M |
| Net Change in Cash | - | -184.17M | -157.98M | 28.78M | 35.22M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 32.5% | 31.3% | 27.4% | 29.0% |
| Operating Margin % | - | 19.6% | 18.5% | 14.6% | 16.8% |
| Net Margin % | - | 14.5% | 13.4% | 10.7% | 11.8% |
| ROE % | - | 14.3% | 12.9% | 8.4% | 9.4% |
| ROCE % | - | 16.1% | 13.4% | 8.7% | 9.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Conestoga Capital Advisors, LLC | 2.31% | 7.01M | $152.07M |
| 2 | Neuberger Berman Group, LLC | 1.86% | 5.62M | $122.00M |
| 3 | Times Square Capital Management, LLC | 1.15% | 3.47M | $75.40M |
| 4 | Van Berkom & Associates Inc. | 0.98% | 2.97M | $64.43M |
| 5 | Artisan Partners Limited Partnership | 0.86% | 2.60M | $56.45M |
| 6 | BAMCO Inc. | 0.82% | 2.49M | $54.14M |
| 7 | Morgan Stanley | 0.43% | 1.31M | $28.33M |
| 8 | Credit Agricole S.A. | 0.43% | 1.30M | $28.16M |
| 9 | Wellington Management Group, LLP | 0.41% | 1.25M | $27.17M |
| 10 | Ranger Investment Management, L.p. | 0.39% | 1.19M | $25.74M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STVN
Two healthcare conferences in New York and London will include Stevanato Group - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQSlFQSjIzUjB5dGQwek1QS2VRcWVTcmZnZ3VwY1RjVlFZSTV4aXRxV3Rkc0lmV3ZFY25SdVc0aGhhT1E1a1ROZTNrMXQyNTR3Zlphd3BoTU5IWGxlWTYwMVVQMnMzdVZPMy1TNmIxWG5lX3doanhaWEQtdjN4Ti1ueXJjWWpjSUotQ3RKVm…
Stevanato Group S.p.A. (STVN) Stock Analysis: Unlocking 21% Potential Upside for Healthcare Investors - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNVGxzejVvbEVOMTJMWjVWenNQeUY2enFKMVBlRmRGakJwNTQzNDRjSTZfNUNHNjRncktZUGhCanV5cVZyNWNLUFVkbTQ5amNpRUEzdDRveDREUkpIZnRSWS1fYmdLbUlveU9tY2JvZm4zSE5jOFh6SzNHZW9TREVmQVBPaEljdXhHWHV1an…
Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPQUlORDRMZTBxdXpJZE04bGs5MjJuOE9mUUxGWXp2RUVBNFhLWG82eWxrenQwSmJxdHBkX3dQZVhtcE5zZ3B4ZWJDRnBQRjRnbXBIbG0yNm9kMTFpWF9nQWFmTlpTTnE0UXJzQm1QYXhjcWdGamkyQWJBWnc1T2xqY1FnUmxzcFUyT21MQ2…
Wellington Management Group LLP Makes New Investment in Stevanato Group S.p.A. $STVN - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOME1Ub2ZLR1dvS1lad0VMSVU5WFBWMmNEOVJrblBQY2VJeXFkUEpNRG5JWVdKNTBuaHRjNWI1Zjk4TUNxbTcwRDN4dzBkLTFEM0tESDAyOUpNeElPd1NRcC1pZzBWQmZEZVJSQnBrLWZzTnFmdVJ5VWNCNlI2SW9sTFcyelg3Zl9Ed2ZzTj…
Trading Systems Reacting to (STVN) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPelp0X1VuZmJVZk5YOEZZTWU1RmhXNlM2MHlfVU9YQUtyRUNUcElPMDRWc1VXdUQ0c2k5ekZudFg5akN4YlJuVTFSM1FLdmd5aXFmWDB5LWZlOXJMR0Y3XzdqZm1KajlZMzVfd29sckZ6XzRQZGtFTEZDQ1FvWHlZN0ktQ01ocVdhRzVwQm…
STVN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBRSDRWMDg1YWdnQXFVMWVqRDFacFM4VjN0YlRxVjl2YUxlQlJURHBFR2VuOFM2Ml93bTFETWY5NG04N1dmRWtvSW1uSFNaUGNyTC1WQ3NVaFNvSDJZbWxpTWRUM2ZsM2tScnE3anM4UWp0WjhaWkxN?oc=5" target="_blank">STVN Fo…
STVN — Frequently Asked Questions
What is the current share price of Stevanato Group S.p.A. (STVN)?
As of 2026-09-19 21:16 PDT, Stevanato Group S.p.A. (STVN) trades at $20.32 on NYSE. Its 52-week range is $13.38 to $27.51.
What is the market capitalisation of STVN?
Stevanato Group S.p.A. (STVN) has a market capitalisation of $1.01B on NYSE.
What is the P/E ratio of STVN?
STVN trades at a trailing price-to-earnings (P/E) ratio of 36.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.31.
Does STVN pay a dividend?
Stevanato Group S.p.A. (STVN) currently offers a dividend yield of 0.27%.
What is the return on equity (ROE) of STVN?
STVN has a return on equity (ROE) of 9.13%. Its return on capital employed (ROCE) is 9.90%.
Is STVN a good stock to buy?
This page provides a data-driven analysis of Stevanato Group S.p.A. (STVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.